Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Albuminuria
/ drug therapy
Aminobutyrates
/ pharmacology
Angiotensin Receptor Antagonists
/ pharmacology
Animals
Biphenyl Compounds
/ pharmacology
Blood Pressure
/ drug effects
Diabetic Nephropathies
/ drug therapy
Drug Combinations
Inflammation
/ prevention & control
Male
Mice
Mice, Inbred C57BL
Mice, Inbred NOD
Oxidative Stress
Valsartan
/ administration & dosage
cGMP-AMP synthase
diabetic kidney disease
sacubitril
stimulator of interferon genes
valsartan
Journal
American journal of physiology. Renal physiology
ISSN: 1522-1466
Titre abrégé: Am J Physiol Renal Physiol
Pays: United States
ID NLM: 100901990
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
20
4
2021
medline:
31
7
2021
entrez:
19
4
2021
Statut:
ppublish
Résumé
Although renin-angiotensin blockade has shown beneficial outcomes in patients with diabetes, renal injury progresses in most of these patients. Therefore, there remains a need for new therapeutic targets in diabetic kidney disease. Enhancement of vasoactive peptides, such as natriuretic peptides, via neprilysin inhibition, has been a new approach. A first-in-class drug, sacubitril/valsartan (Sac/Val), a combination of the angiotensin II receptor blocker Val and neprilysin inhibitor prodrug Sac, has been shown to be more effective than renin-angiotensin blockade alone in the treatment of heart failure with reduced ejection fraction. In this study, we tested the effects of Sac/Val in diabetic kidney disease. We administered Sac/Val or Val to two type 2 diabetes mouse models,
Identifiants
pubmed: 33870733
doi: 10.1152/ajprenal.00614.2020
pmc: PMC8285642
doi:
Substances chimiques
Aminobutyrates
0
Angiotensin Receptor Antagonists
0
Biphenyl Compounds
0
Drug Combinations
0
Valsartan
80M03YXJ7I
sacubitril and valsartan sodium hydrate drug combination
WB8FT61183
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
F1133-F1151Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK116567
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001431
Pays : United States
Organisme : HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
ID : TL1TR001431
Organisme : HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ID : 5R01DK116567
Références
EMBO Rep. 2020 Apr 3;21(4):e49799
pubmed: 32202065
Clin J Am Soc Nephrol. 2013 Sep;8(9):1603-5
pubmed: 23788618
Eur J Pharmacol. 2020 Oct 5;884:173444
pubmed: 32739172
J Exp Med. 2018 May 7;215(5):1287-1299
pubmed: 29622565
J Biol Chem. 2017 Jul 21;292(29):12018-12024
pubmed: 28596381
Diabetes. 2001 Dec;50(12):2792-808
pubmed: 11723063
Trends Cell Biol. 2020 Aug;30(8):594-605
pubmed: 32546434
Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1519-F1525
pubmed: 30110568
J Clin Invest. 2014 Jun;124(6):2333-40
pubmed: 24892707
Life Sci. 1981 Jan 5;28(1):89-94
pubmed: 7219045
Nat Rev Cardiol. 2014 Jul;11(7):403-12
pubmed: 24820868
Cell Metab. 2019 Oct 1;30(4):784-799.e5
pubmed: 31474566
J Card Fail. 2018 Apr;24(4):266-275
pubmed: 29325796
Am J Transl Res. 2017 Dec 15;9(12):5473-5484
pubmed: 29312499
N Engl J Med. 2011 Jul 7;365(1):32-43
pubmed: 21732835
J Clin Invest. 1991 Nov;88(5):1636-42
pubmed: 1658047
PeerJ. 2020 Jun 19;8:e9196
pubmed: 32596035
Diabetes. 2006 Nov;55(11):2993-3003
pubmed: 17065335
Am J Physiol Renal Physiol. 2020 Jul 1;319(1):F63-F75
pubmed: 32463726
Circulation. 2004 Sep 21;110(12):1620-5
pubmed: 15337695
Circulation. 1998 Jun 16;97(23):2323-30
pubmed: 9639376
Diabetes. 2017 Nov;66(11):2840-2848
pubmed: 28864549
PLoS One. 2012;7(8):e43238
pubmed: 22916229
Diabetes. 2019 Jun;68(6):1099-1108
pubmed: 31109939
PLoS One. 2014 Feb 19;9(2):e89201
pubmed: 24586593
Kidney Dis (Basel). 2017 Jul;3(1):24-32
pubmed: 28785561
JAMA. 2011 Jun 22;305(24):2532-9
pubmed: 21693741
Compr Physiol. 2011 Jul;1(3):1175-232
pubmed: 23733640
J Am Soc Nephrol. 2011 Mar;22(3):545-53
pubmed: 21355053
Popul Health Metr. 2010 Oct 22;8:29
pubmed: 20969750
Card Fail Rev. 2016 May;2(1):40-46
pubmed: 28785451
Expert Opin Investig Drugs. 2004 Jun;13(6):643-52
pubmed: 15174950
J Am Soc Nephrol. 2016 May;27(5):1362-78
pubmed: 26424786
Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1164-F1168
pubmed: 31509010
Nephrourol Mon. 2012 Summer;4(3):524-9
pubmed: 23573479
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
Science. 2019 Mar 8;363(6431):
pubmed: 30846571
Nat Rev Dis Primers. 2015 Jul 30;1:15018
pubmed: 27188921
Nature. 1988 Mar 3;332(6159):78-81
pubmed: 2964562
J Am Soc Nephrol. 2009 Dec;20(12):2503-12
pubmed: 19729434
Cell Rep. 2019 Oct 29;29(5):1261-1273.e6
pubmed: 31665638
Nature. 2009 Oct 8;461(7265):788-92
pubmed: 19776740
Circulation. 2005 Jan 25;111(3):315-20
pubmed: 15655136
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Curr Diabetes Rev. 2014 Mar;10(2):131-45
pubmed: 24809394
J Clin Pharmacol. 2010 Apr;50(4):401-14
pubmed: 19934029
N Engl J Med. 2014 Apr 17;370(16):1514-23
pubmed: 24738668
Biochim Biophys Acta Mol Basis Dis. 2017 May;1863(5):1106-1114
pubmed: 27497523
Nat Rev Immunol. 2017 Jun;17(6):363-375
pubmed: 28393922
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Hum Immunol. 2018 Jun;79(6):494-498
pubmed: 29601852
J Am Soc Nephrol. 2018 Jan;29(1):118-137
pubmed: 29089371
Endocr Rev. 2006 Feb;27(1):47-72
pubmed: 16291870
Am J Cardiol. 2012 Aug 1;110(3):383-91
pubmed: 22521308
J Hypertens. 2020 Apr;38(4):755-764
pubmed: 31790054
Methods Mol Biol. 2014;1105:419-37
pubmed: 24623245